LATS2 is a modulator of estrogen receptor alpha

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 53-64

  Lit, Lei Cheng ^a   Scott, Susan ^a   Zhang, Hua ^a   Stebbing, Justin ^a   Photiou, Andrew ^a   Giamas, Georgios ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; ER ; Estrogen receptor; LATS2; NCoR

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR ALPHA; LARGE TUMOR SUPPRESSOR HOMOLOG 2; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN P27; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR RECEPTOR CO-REPRESSOR 1; PROLIFERATING CELL NUCLEAR ANTIGEN; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84873041700     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM: The nuclear receptor superfamily: the second decade. Cell 83(6): 835-839, 1995.
2. Stebbing J, Delaney G and Thompson A: Breast cancer (nonmetastatic). Clin Evid (Online), 2007.
3. Dutertre M and Smith CL: Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17(7): 1296-1314, 2003.
4. Arnold SF, Obourn JD, Jaffe H and Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 9(1): 24-33, 1995.
5. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC and Baldwin MA: Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Molecular & cellular proteomics: MCP. Mar 8(3): 467-480, 2009.
6. Britton DJ, Scott GK, Schilling B, Atsriku C, Held JM, Gibson BW, Benz CC and Baldwin MA: A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Amer Soc Mass Spectrometry 19(5): 729-740, 2008.
7. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC and Ali S: Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32): 4921-4931, 2002.
8. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL and Rowan BG: Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC βiochem 10: 36, 2009.
9. Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15(9): 2174-2183, 1996.
10. Castano E, Vorojeikina DP and Notides AC: Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochemical J 326(Pt 1): 149-157, 1997.
11. Chen D, Pace PE, Coombes RC and Ali S: Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Molec Cellular Biol 19(2): 1002-1015,1999.
12. Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S and Kato S: Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Molec Cellular Biol 19(8): 5363-5372, 1999.
13. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM and Cheng JQ: IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 285(6): 3676-3684, 2010.
14. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J and Lannigan DA: pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molec Cellular Biol 18(4): 1978-1984, 1998.
15. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, Landberg G and Michalides R: PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125(1): 1-12, 2011.
16. Lannigan DA: Estrogen receptor phosphorylation. Steroids 68(1): 1-9, 2003.
17. Rogatsky I, Trowbridge JM and Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 274(32): 22296-22302, 1999.
18. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61(16): 5985-5991, 2001.
19. Giamas G, Castellano L, Feng Q, Knippschild U, Jacob J, Thomas RS, Coombes RC, Smith CL, Jiao LR and Stebbing J: CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions. Nucleic Acids Res 37(9): 3110-3123,2009.
20. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ and Stebbing J: Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Med 17(6): 715-719, 2011.
21. Arnold SF, Vorojeikina DP and Notides AC: Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 270(50): 30205-30212, 1995.
22. Arnold SF, Melamed M, Vorojeikina DP, Notides AC and Sasson S: Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol Endocrinol 11(1): 48-53, 1997.
23. Al-Dhaheri MH and Rowan BG: Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation. Mol Endocrinol 21(2): 439-456, 2007.
24. Le Goff P, Montano MM, Schodin DJ and Katzenellenbogen BS: Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biological Chem 269(6): 4458-4466, 1994.
25. Font de Mora J, Brown M: AIB1 is a conduit for kinasemediated growth factor signaling to the estrogen receptor Mol Cellular Biol 20(14): 5041-5047, 2000
26. Fritah A, Saucier C, Mester J, Redeuilh G and Sabbah M: p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol Cellular Biol 25(6): 2419-2430, 2005.
27. Glass CK and Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Development 14(2): 121-141, 2000.
28. Rosenfeld MG and Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biological Chem 276(40): 36865-36868, 2001.
29. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG and Rose DW: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Nat Acad Sci USA 95(6): 2920-2925, 1998.
30. Varlakhanova N, Snyder C, Jose S, Hahm JB and Privalsky ML: Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol 30(6): 1434-1445, 2010.
31. Jacq X, Brou C, Lutz Y, Davidson I, Chambon P and Tora L: Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 79(1): 107-117, 1994.
32. Lee HH, Vo MT, Kim HJ, Lee UH, Kim CW, Kim HK, Ko MS, Lee WH, Cha SJ, Min YJ, Choi DH, Suh HS, Lee BJ, Park JW and Cho WJ: Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin. J Biol Chem 285(23): 17329-17337, 2010.
33. Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y and Nojima H: Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 63(2): 263-270, 2000.
34. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, Tamai K and Nojima H: The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes to cells: devoted to molecular & cellular mechanisms 9(5): 383-397, 2004.
35. Abe Y, Ohsugi M, Haraguchi K, Fujimoto J and Yamamoto T: LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis. FEBS Letters 580(3): 782-788, 2006.
36. Li Y, Pei J, Xia H, Ke H, Wang H and Tao W: Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 22(28): 4398-4405, 2003.
37. Kamikubo Y, Takaori-Kondo A, Uchiyama T and Hori T: Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. Journal Biological Chem 278(20): 17609-17614, 2003.
38. Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T, Kelekar A and Tao W: Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res 298(2): 329-338, 2004.
39. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H and Oren M: A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Development 20(19): 2687-2700, 2006.
40. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP and Bai C: The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol Aug 18(8): 2011-2023, 2004.
41. Visser S and Yang X: LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 9(19): 3892-3903, 2010.
42. Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M and Uchiyama T: Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 112(9): 3856-3866, 2008.
43. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G and Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neuroscience Res 56(4): 450-458, 2006.
44. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 11(4): 1380-1385, 2005.
45. Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH, Lin JT, Chen YL and Lu PJ: MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 315(15): 2529-2538, 2009.
46. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G and Linn SC: Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathology 217(3): 372-379, 2009.
47. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD and Pollack JR: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PloS One 4(7): e6146, 2009.
48. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Nat Cancer Inst 82(13): 1107-1112, 1990.
49. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM and Lippman ME: GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92(2): 141-149, 2005.
50. Schreihofer DA, Stoler MH and Shupnik MA: Differential expression and regulation of estrogen receptors (ERs) in rat pituitary and cell lines: estrogen decreases ERalpha protein and estrogen responsiveness. Endocrinology 141(6): 2174-2184, 2000.
51. Wijayaratne AL and McDonnell DP: The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biological Chem 276(38): 35684-35692, 2001.
52. Lin Z, Reierstad S, Huang CC and Bulun SE: Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res 67(10): 5017-5024, 2007.
53. Ekholm SV and Reed SI: Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Current Opinion in cell Biology 12(6): 676-684, 2000.
54. Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol 133(8): 501-509, 2007.
55. Hotchkiss RS, Strasser A, McDunn JE and Swanson PE: Cell death. New Engl J Med 361(16): 1570-1583, 2009.
56. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptornegative tumours and in situ cancer. British J Cancer 69(1): 135-139, 1994.
57. Sabbah M, Courilleau D, Mester J and Redeuilh G: Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Nat Acad Sci USA 96(20): 11217-11222, 1999.
58. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88(3): 405-415, 1997.